Cargando…
Treatments for chronic psychosis
Psychosis is a mental condition characterized by hallucinations, delusions, and thought disorder; it spans diagnostic entities that respond to similar therapeutic approaches. Psychosis has no fully described tissue pathology, as vet, but is still identified and assessed symptomatically. The first ge...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181661/ https://www.ncbi.nlm.nih.gov/pubmed/22033485 |
_version_ | 1782212783898624000 |
---|---|
author | Tamminga, Carol A. Lahti, Adrienne C. |
author_facet | Tamminga, Carol A. Lahti, Adrienne C. |
author_sort | Tamminga, Carol A. |
collection | PubMed |
description | Psychosis is a mental condition characterized by hallucinations, delusions, and thought disorder; it spans diagnostic entities that respond to similar therapeutic approaches. Psychosis has no fully described tissue pathology, as vet, but is still identified and assessed symptomatically. The first generation of antipsychotic drugs was developed in the middle of the 20th century. The second generation of drugs arrived in the 1990s. This new group of antipsychotic drugs has potent therapeutic actions on the positive symptoms of psychosis with far fewer side effects, especially motor effects. However, each of the new drugs has its own characteristic clinical and pharmacological features that affect individual patient response. Understanding these individual drug characteristics can promote optimal drug choice and use in conditions of chronic psychosis. |
format | Online Article Text |
id | pubmed-3181661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | Les Laboratoires Servier |
record_format | MEDLINE/PubMed |
spelling | pubmed-31816612011-10-27 Treatments for chronic psychosis Tamminga, Carol A. Lahti, Adrienne C. Dialogues Clin Neurosci Clinical Research Psychosis is a mental condition characterized by hallucinations, delusions, and thought disorder; it spans diagnostic entities that respond to similar therapeutic approaches. Psychosis has no fully described tissue pathology, as vet, but is still identified and assessed symptomatically. The first generation of antipsychotic drugs was developed in the middle of the 20th century. The second generation of drugs arrived in the 1990s. This new group of antipsychotic drugs has potent therapeutic actions on the positive symptoms of psychosis with far fewer side effects, especially motor effects. However, each of the new drugs has its own characteristic clinical and pharmacological features that affect individual patient response. Understanding these individual drug characteristics can promote optimal drug choice and use in conditions of chronic psychosis. Les Laboratoires Servier 2001-12 /pmc/articles/PMC3181661/ /pubmed/22033485 Text en Copyright: © 2001 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Research Tamminga, Carol A. Lahti, Adrienne C. Treatments for chronic psychosis |
title | Treatments for chronic psychosis |
title_full | Treatments for chronic psychosis |
title_fullStr | Treatments for chronic psychosis |
title_full_unstemmed | Treatments for chronic psychosis |
title_short | Treatments for chronic psychosis |
title_sort | treatments for chronic psychosis |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181661/ https://www.ncbi.nlm.nih.gov/pubmed/22033485 |
work_keys_str_mv | AT tammingacarola treatmentsforchronicpsychosis AT lahtiadriennec treatmentsforchronicpsychosis |